KCT0003384已完成未知
The continuation of gefitinib treatment beyond progression in non-small cell lung cancer patients with EGFR mutation: A phase II single arm prospective study
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 入组人数
- 51
研究概览
简要总结
In patients with EGFR-mutant NSCLC who experience progression, it is beneficial to maintain gefitinib treatment with local treatment such as radiotherapy until symptomatic progression. However, in patients with pleural metastasis or effusion, continuation of gefitinib beyond progression should be carefully determined. .
研究设计
- 研究类型
- Interventional Study
入排标准
- 年龄范围
- 18(Year) 至 o Limit（—）
- 性别
- All
入选标准
- •?Histologically confirmed stage IIIB/IV or recurrent NSCLC with activating EGFR mutation in exon 18 through exon 21 except T790M
- •?Patients who achieved complete/partial response more than 4 months or stable disease more than 6 months with first-line or second line gefitinib, Patients who experience disease progression by RECIST 1.1 criteria
- •?Age = 18years
- •?ECOG performance status of 0 to 2
- •?Adequate organ function as evidenced by the following; Absolute neutrophil count > 1.5 x 109/L; platelets > 100 x 109/L; total bilirubin =1.5 UNL; AST and/or ALT < 5 UNL, CCr = 50mL/min
- •? Gefitinib baseline adverse event = Grade 2
- •?Written informed consent form
排除标准
- •?Prior treatment with EGFR TKI
- •?Patients who required dose reduction of gefitinib
- •?Surgery undertaken less than 4 weeks before the study
- •?Localized radiotherapy unless completed more than 2 weeks before the study
- •?Uncontrolled systemic illness such as DM, CHF, unstable angina, hypertension or arrhythmia
- •?Pregnant or nursing women ( Women of reproductive potential have to agree to use an effective contraceptive method (hormonal or barrier methods))
- •?Uncontrolled symptomatic brain metastasis
- •?Prior history of malignancy within 5 years from study entry except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer, well-treated thyroid cancer
- •?Concomitant use of CYP3A4 inducers/inhibitors
- •?Prolonged QT interval in ECG (QTc >450 msec)
研究者
相似试验
Unknown
2 期
The Continuation of Gefitinib Treatment Beyond Progression in Non-small Cell Lung Cancer Patients With EGFR MutationNon-small Cell Lung CancerNCT03399669Samsung Medical Center100
已完成
2 期
Erlotinib Treatment Beyond Progression in EGFR Mutant NSCLCNon-small Cell Lung CancerNCT02064491Finnish Lung Cancer Group18
终止
2 期
Iressa Re-challenge in Advanced NSCLC EGFR-mutated PatientsLung CancerNCT02025218Amsterdam UMC, location VUmc21
Unknown
2 期
First Line Gefitinib by FDG-PET Metabolic ResponseNon-small Cell Lung CancerNCT01510990Asan Medical Center60
已完成
2 期
A phase II study of gefitinib with concurrent thoracic radiotherapy in patients with unresectable, stage III Non-Small Cell Lung Cancer harboring EGFR mutations.on-Small Cell Lung CancerJPRN-UMIN000008366West Japan Oncology Group28